As of 30 Sep 2025, 76 institutional investors reported holding 13,927,352 shares of Protalix BioTherapeutics, Inc. - COM (PLX).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 544,705 | $980,577 | +$31,640 | $1.80 | 6 |
| 2025 Q3 | 13,927,352 | $30,914,125 | +$4,618,112 | $2.22 | 76 |
| 2025 Q2 | 11,908,531 | $17,628,861 | +$1,905,095 | $1.48 | 62 |
| 2025 Q1 | 8,186,092 | $20,953,817 | +$9,615,817 | $2.56 | 63 |
| 2024 Q4 | 4,467,137 | $8,398,304 | +$2,201,791 | $1.88 | 45 |
| 2024 Q3 | 3,383,529 | $3,451,053 | -$2,254,204 | $1.02 | 43 |
| 2024 Q2 | 5,625,789 | $6,582,747 | -$4,803,260 | $1.17 | 65 |
| 2024 Q1 | 9,445,037 | $11,901,089 | -$599,933 | $1.26 | 61 |
| 2023 Q4 | 29,265 | $52,092 | $1.78 | 1 | |
| 2023 Q3 | 9,165,851 | $15,208,863 | -$99,206 | $1.66 | 61 |
| 2023 Q2 | 8,968,409 | $17,889,394 | +$11,985,895 | $2.00 | 65 |
| 2023 Q1 | 2,937,388 | $6,146,180 | +$407,625 | $2.10 | 34 |
| 2022 Q4 | 3,567,572 | $4,870,303 | +$111,553 | $1.37 | 27 |
| 2022 Q3 | 3,547,939 | $3,695,821 | +$2,398,549 | $1.04 | 25 |
| 2022 Q2 | 1,192,775 | $1,298,025 | +$26,651 | $1.09 | 28 |
| 2022 Q1 | 1,215,914 | $1,286,770 | -$1,765,499 | $1.06 | 28 |
| 2021 Q4 | 2,920,028 | $2,434,760 | -$1,655,011 | $0.83 | 22 |
| 2021 Q3 | 4,413,909 | $5,910,000 | +$96,768 | $1.33 | 34 |
| 2021 Q2 | 4,314,199 | $8,238,000 | -$19,328,753 | $1.91 | 30 |
| 2021 Q1 | 8,820,909 | $39,345,460 | +$21,166,114 | $4.46 | 35 |
| 2020 Q4 | 4,086,381 | $14,834,000 | -$2,665,295 | $3.63 | 20 |
| 2020 Q3 | 4,760,619 | $18,439,000 | -$1,924,402 | $3.87 | 22 |
| 2020 Q2 | 5,259,161 | $19,813,000 | -$2,816,759 | $3.79 | 24 |
| 2020 Q1 | 5,995,054 | $14,095,000 | +$12,574,679 | $2.35 | 15 |
| 2019 Q4 | 644,194 | $2,111,000 | +$2,111,015 | $3.28 | 7 |